Goldman Sachs’s Galectin Therapeutics GALT Stock Holding History

Goldman Sachs’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,200	Closed	-$1K	–	6959
2016 Q3	$1K	Hold	1,200	–	–	﹤0.01%	6978
2016 Q2	$2K	Sell	1,200 -498,100	-100%	-$731K	﹤0.01%	6971
2016 Q1	$714K	Hold	499,300	–	–	﹤0.01%	4387
2015 Q4	$819K	Buy	499,300 +497,500	+27,639%	+$1.14M	﹤0.01%	4487
2015 Q3	$4K	Buy	1,800 +600	+50%	+$1.42K	﹤0.01%	7214
2015 Q2	$3K	Sell	1,200 -1,200	-50%	-$3.62K	﹤0.01%	7214
2015 Q1	$8K	Sell	2,400 -1,200	-33%	-$4.29K	﹤0.01%	6984
2014 Q4	$12K	Sell	3,600 -2,500	-41%	-$11K	﹤0.01%	7029
2014 Q3	$31K	Sell	6,100 -11,600	-66%	-$90.3K	﹤0.01%	6925
2014 Q2	$244K	Sell	17,700 -20,200	-53%	-$251K	﹤0.01%	6039
2014 Q1	$580K	Buy	+37,900	New	+$540K	﹤0.01%	5157

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's GALT Position: Q2 2026 in Review

Goldman Sachs reduced its Galectin Therapeutics (GALT) stake by 60% in Q2 2026, selling an estimated $286K and leaving 74,554 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #5934.

Goldman Sachs first reported a position in GALT in Q1 2014 and has held it in 40 quarters since. The position peaked at $1.28M in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Goldman Sachs held 74,554 shares of Galectin Therapeutics worth $346K as of Q2 2026.
Goldman Sachs sold 110,183 Galectin Therapeutics shares in Q2 2026, an estimated $286K.
Galectin Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5934 holding.
Goldman Sachs first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 40 quarters since.
Goldman Sachs's Galectin Therapeutics position peaked at $1.28M in Q4 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.